Mersana raises $35m, names former Millennium president CEO
This article was originally published in Scrip
Seventeen-year Millennium Pharmaceuticals veteran Anna Protopapas began her first day as president and CEO of Mersana Therapeutics on 2 March with an announcement that the antibody-drug conjugate (ADC) specialist closed a $35m Series B venture capital round.
You may also be interested in...
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.